Brokerages forecast that Replimune Group Inc (NASDAQ:REPL) will post ($0.35) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Replimune Group’s earnings, with estimates ranging from ($0.36) to ($0.33). The company is scheduled to report its next quarterly earnings results on Thursday, July 4th.
On average, analysts expect that Replimune Group will report full year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.49) to ($1.13). For the next fiscal year, analysts forecast that the company will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.90) to ($1.48). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Replimune Group.
A number of research analysts recently commented on REPL shares. Wedbush started coverage on shares of Replimune Group in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $24.00 target price on the stock. Zacks Investment Research downgraded shares of Replimune Group from a “hold” rating to a “sell” rating in a research report on Saturday, March 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Replimune Group presently has a consensus rating of “Hold” and an average price target of $26.50.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. acquired a new stake in Replimune Group during the 3rd quarter worth $5,379,000. UBS Oconnor LLC boosted its stake in Replimune Group by 30.1% during the 4th quarter. UBS Oconnor LLC now owns 68,531 shares of the company’s stock worth $685,000 after purchasing an additional 15,866 shares during the period. BlackRock Inc. boosted its stake in Replimune Group by 79.9% during the 4th quarter. BlackRock Inc. now owns 716,242 shares of the company’s stock worth $7,164,000 after purchasing an additional 318,115 shares during the period. Bank of New York Mellon Corp acquired a new stake in Replimune Group during the 3rd quarter worth $319,000. Finally, Emerald Advisers LLC boosted its stake in Replimune Group by 7.1% during the 1st quarter. Emerald Advisers LLC now owns 697,898 shares of the company’s stock worth $10,622,000 after purchasing an additional 46,428 shares during the period. 59.58% of the stock is currently owned by hedge funds and other institutional investors.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Recommended Story: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.